This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Prevenar, Pneumococcal 7–valent conjugate vaccine (Diphtheria CRM197 protein conjugate), PCV7
Description: Prevnar, the first pneumococcal conjugate vaccine licensed in the United States (U.S.), was approved by the FDA for active immunization to prevent invasive pneumococcal disease (IPD) in February 2000. The active immunogens in Prevnar are capsular polysaccharides derived from seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) conjugated to diphtheria CRM197 protein. The serotypes in the vaccine were originally selected because, at that time, they accounted for approximately 80% of IPD in young children in North America. A high level of efficacy (aggregated for the 7 serotypes) in preventing vaccine serotype IPD was demonstrated in a clinical endpoint vaccine efficacy trial in infants. In October, 2002, an additional Prevnar indication was approved for active immunization of infants and toddlers against otitis media caused by vaccine serotypes.
In October 2000, the Advisory Committee on Immunization Practices (ACIP) recommended Prevnar for all children aged < 2 years and for older children at increased risk of IPD. Since the introduction of Prevnar in 2000, the rates of IPD caused by vaccine serotypes declined among U.S. children in the age group targeted by vaccination (direct effects) and among unimmunized older children and adults (indirect or herd immunity). By 2007, in children aged < 5 years, rates of IPD caused by serotypes contained in Prevnar declined by 99%. Although the overall rate of IPD caused by all pneumococcal serotypes was 76% lower in 2007 compared with the years preceding Prevnar introduction, overall IPD rates began to level off in 2002. This leveling off was due to an increase in the incidence of IPD caused by non-Prevnar serotypes, particularly serotype 19A. The six additional pneumococcal serotypes (1,3,5,6A, 7F, and 19A)contained in Prevnar 13 were responsible for approximately 62% of IPD cases in children < 5 years of age in 2007. In this same age group, the thirteen serotypes contained in Prevnar-13 were responsible for approximately 64% of IPD cases in 2007.
Beginning in 2013, Pfizer began reporting Prevnar and Prevnar 13 revenue together under Prevnar Family. The Company also stated that many markets have transitioned from the use of Prevnar/Prevenar (7-valent) to Prevnar 13/Prevenar 13, generally resulting in a lower revenue trend for Prevnar/Prevenar (7-valent). Based on this information we are recording Prevnar family revenue under the Prevnar 13 drug profile.
Prevnar was originally developed by Wyeth.
Pfizer and Wyeth
In January 2009, Pfizer and Wyeth announced that they entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction currently valued at $50.19 per share, or a total of approximately $68 billion. In October 2009, Pfizer completed its acquisition of Wyeth.
Takeda and Pfizer
In June 2012, Takeda and Pfizer announced that they have concluded an agreement that, as of December 31, 2012, Takeda...See full deal structure in Biomedtracker
Partners: Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: